Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743611 · ClinicalTrials.gov registry record · Phase 1
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
A Phase 1 study, sponsored by Bellicum Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02743611 is a Phase 1 study that was terminated before completion, run by Bellicum Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT02743611, a Phase 1 study, was terminated before completion, sponsored by Bellicum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.
Interventions
- DRUG Rimiducid
- BIOLOGICAL BPX-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-04-14 |
| Est. Completion | 2020-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743611
The ClinicalTrials.gov registry entry for NCT02743611 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimiducid is the first listed.
NCT02743611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02743611 about?
NCT02743611 is a clinical study titled "Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma". The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and targ...
What is the current status of trial NCT02743611?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-04-14. Estimated completion is 2020-07-19.
What interventions are being tested in trial NCT02743611?
The interventions under investigation include: Rimiducid (DRUG), BPX-701 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02743611?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.